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Introduction
The molecular chaperone Hsp90 (heat shock protein 90) main-
tains the conformation, stability, and activity of several key onco-
genic proteins, such as EGF receptor (EGFR), cyclin-dependent 
kinases, Raf, and p53, which are collectively known as Hsp90 
client proteins (Whitesell and Lindquist, 2005). The chaperone 
function of Hsp90 requires the formation of a multichaperone 
complex, which is dependent on the hydrolysis of ATP and 
ADP/ATP exchange. A geldanamycin (GA) analogue, which 
inhibits Hsp90 by blocking its intrinsic ATPase activity, was the 
first in class inhibitor of Hsp90 in human clinical trials for 
cancer therapy. Inhibition of Hsp90 function by GA disrupts 
the interaction of Hsp90 with its client proteins and leads to 
their proteasome pathway-dependent degradation (Zhang and 
Burrows, 2004).
Autophagy mediates the bulk degradation of intracellular 
components such as macromolecule complexes and subcellular 
organelles through lysosomal-dependent mechanisms and is 
essential for the maintenance of cellular homeostasis (Meijer, 
2003). Three modes of autophagy have been identified in mam-
mals (Levine and Klionsky, 2004). Macroautophagy cargo is 
sequestered into a specialized double-membrane structure called 
an autophagosome. Autophagosomes then fuse with lysosomes, 
and its content is subsequently degraded by hydrolytic enzymes. 
Microautophagy cargo is generated by direct budding of the 
lysosomal membrane. In chaperone-mediated autophagy (CMA), 
substrates are recognized by a chaperone complex containing 
Hsc70 (heat shock cognate of 70 kD) and delivered into lyso-
somes through interactions with LAMP-2A (lysosome-associated 
membrane protein 2A). CMA is activated during prolonged 
nutrient deprivation, which results in the degradation of cyto-
solic proteins in a molecule by molecule fashion (Dice, 2007). 
P
romoting the degradation of Hsp90 client proteins by 
inhibiting Hsp90, an important protein chaperone, 
has been shown to be a promising new anticancer 
strategy. In this study, we show that an oxazoline analogue 
of apratoxin A (oz-apraA), a cyclodepsipeptide isolated 
from a marine cyanobacterium, promotes the degradation 
of Hsp90 clients through chaperone-mediated autophagy 
(CMA). We identify a KFERQ-like motif as a conserved 
pentapeptide sequence in the kinase domain of epidermal 
growth factor receptor (EGFR) necessary for recognition as 
a CMA substrate. Mutation of this motif prevents EGFR deg-
radation by CMA and promotes the degradation of EGFR 
through  the  proteasomal  pathway  in  oz-apraA–treated 
cells. Oz-apraA binds to Hsc70/Hsp70. We propose that 
apratoxin A inhibits Hsp90 function by stabilizing the inter-
action of Hsp90 client proteins with Hsc70/Hsp70 and thus 
prevents their interactions with Hsp90. Our study provides 
the first examples for the ability of CMA to mediate degra-
dation of membrane receptors and cross talks of CMA and 
proteasomal degradation mechanisms.
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Results
Impact of apratoxin A and its oxazoline 
analogue on Hsp90 chaperone complexes
To study the molecular mechanism of apratoxin A (Fig. 1 A), 
we performed retrospective data mining by identifying the gene 
expression signature of apratoxin A (Fig. S1 A) from a previous 
study (Luesch et al., 2006) and compared it with gene expres-
sion  signatures  of  different  compounds  in  the  Connectivity 
Map database (Lamb et al., 2006). The apratoxin A signatures 
from 3- and 6-h treatment exhibited a high degree of similarity 
to the gene expression profile from the well-established Hsp90 
inhibitor 17-allylamino-GA (n = 18, P < 0.001; Fig. S1 B). 
Consistent with an effect on protein chaperones, apratoxin A 
significantly induced expression of several heat shock–responsive 
genes, including HSPA1B, DNAJB1, HSPA6, DDIT4, DNAJB9, 
and BAG3 (Fig. S1 A and Tables S1 and S2). We reperformed the 
analysis of apratoxin A signatures by removing heat shock–
responsive genes to exclude toxicological effects (Meyer et al., 
1995; Schiaffonati and Tiberio, 1997). The signature of apra-
toxin A treatment with heat shock–responsive genes subtracted 
The relevance of CMA for mediating the degradation of non-
cytosolic proteins, if any, remains unknown.
Apratoxin A, a cyclodepsipeptide isolated from the marine 
cyanobacterium Lyngbya majuscula, exhibits cytotoxic activity 
against several cancer cell lines (Luesch et al., 2006) and has 
shown  to  have  some  activity  against  colon  adenocarcinoma 
C38-derived tumors in an in vivo study (Luesch et al., 2001). 
Apratoxin A was found to induce G1 cell cycle arrest and apop-
tosis (Luesch et al., 2006). However, the cellular and molecular 
mechanisms of apratoxin A remain unknown. Using the clues 
suggested by the gene expression signatures of apratoxin A 
(Luesch et al., 2006), we explored its mechanism of action 
using a synthetic oxazoline analogue of apratoxin A (oz-apraA). 
In this study, we demonstrate that oz-apraA modulates degrada-
tion of Hsp90 client proteins (e.g., EGFR and ErbB2) through 
the CMA pathway. We show that EGFR contains a KFERQ-like 
motif in its kinase domain, and oz-apraA–induced EGFR degra-
dation is dependent on LAMP-2A. Our study demonstrates a 
CMA-mediated mechanism for degradation of multiple Hsp90 
client  proteins,  including  membrane  receptors  in  oz-apraA–
treated cells.
Figure 1.  Apratoxin A and its analogue in-
hibit the Hsp90 pathway. (A) Chemical struc-
ture of the compounds. (B) Oz-apraA reduces 
the levels of Hsp90 client proteins in different cell 
lines. Oz-apraA and GA induce concentration-
dependent decreases of EGFR levels in A549   
cells, ErbB2 levels in MDA-MB-453 cells at 24 h,   
and increases in Hsp70 levels. Lanes 1–5:   
0, 1, 10, 100, and 500 nM; lanes 6–11: 0, 1, 
10, 100, 500, and 1,000 nM. (C) Half-lives 
of  EGFR  and  short-lived  protein  GP130  were   
analyzed in HeLa cells treated with 100 µg/ml 
CHX in the presence of DMSO or 100 nM 
oz-apraA  for  the  indicated  periods  of  time. 
The levels of EGFR were normalized to that 
of -tubulin expression, and results were plot-
ted  against  inhibitor  treatment  time  points. 
(D) Immunoprecipitation (IP) of endogenous 
ErbB2-containing protein complexes from MDA-
MB-453 cells after treatment of 500 nM GA or 
50 nM oz-apraA for 6 h. (E) In vitro Hsp90-
binding assay. SKoV3 cell lysates were incu-
bated with 1 µM GA or 100 nM oz-apraA   
at 4°C for 2 h. ErbB2 was immunoprecipi-
tated, and bound Hsp90 was detected using 
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O-methyl-tyrosine (Fig. 2 A). This compound was assembled 
by a click reaction of a biotin-embodied azide with alkynyl–
oz-apraA; a new analogue of oz-apraA was synthesized based on 
our previous procedure. Our early study indicated that modifica-
tion of the tyrosine tail might have little influence to the biologi-
cal activities (Ma et al., 2006). As desired, bio–oz-apraA remains 
as active as unsubstituted oz-apraA and induces the degradation 
of EGFR in a concentration-dependent manner (Fig. S1 F). Using 
bio–oz-apraA conjugated with streptavidin-agarose, affinity pull-
down assays were performed with lysates of HeLa or HEK293 
cells. Proteins with an apparent molecular mass of 70 kD were 
specifically pulled down with bio–oz-apraA, and this 70-kD pro-
tein was competed away by excess oz-apraA (Fig. 2 B, lanes 
2 and 3). Using mass spectrometry, the 70-kD band was identi-
fied as proteins of the Hsp70 family, including HSPA8 (which 
encodes an Hsc70) and HSPA1B (which encodes an inducible 
Hsp70; Fig. 2 B). Other identified oz-apraA–binding proteins 
include  RARS  (arginyl-tRNA  synthetase  protein)  and  SRP68 
(signal recognition particle protein 68). RARS, a member of the 
class I aminoacyl-tRNA synthetase family, has been reported to 
be associated with Hsp90 (Kang et al., 2000). SRP68, a ribo-
nucleoprotein in the signal peptide recognition particle, is involved 
in docking the nascent polypeptide–ribosome complex at recep-
tors on the ER (Politz et al., 2000). We concentrated further analy-
sis on Hsp70/Hsc70 because they are cochaperones for Hsp90 
and are directly involved in folding of Hsp90 client proteins.
The identity of the 70-kD protein was further confirmed 
by  Western  blotting  using  an  antibody  recognizing  Hsp70/
Hsc70 after the pull-down assay using HeLa cell or HEK293 
cell lysates (Fig. 2 C). The binding of bio–oz-apraA with Hsp70/
Hsc70 binding is specific, as it can be competed away with exces-
sive oz-apraA. To directly analyze the interaction of bio–
oz-apraA with Hsp70 and Hsc70, we next transiently transfected 
HEK293 cells with pcDNA-HA-Hsp70 or pcDNA-HA-Hsc70 
and repeated the pull-down assay followed by Western blotting 
with an anti-HA antibody. As shown in Fig. 2 D, bio–oz-apraA 
can bind to both Hsp70 and Hsc70, and this binding can be 
competed away by excessive oz-apraA, which is consistent with 
the results of the pull-down assay for endogenous Hsp70/Hsc70. 
However, no direct interaction of Hsp90 with bio–oz-apraA was 
detected using a similar assay (unpublished data). Thus, we 
conclude that oz-apraA can bind to Hsp70/Hsc70 but not Hsp90. 
Interestingly, binding of oz-apraA to Hsp70/Hsc70 may also 
disrupt the interaction of Hsp70/Hsc70 with Hsp90 (Fig. S2).
Oz-apraA induces the accumulation  
of ubiquitinated proteins and the  
formation of aggresome
Because the inhibition of Hsp90 by GA has been shown to pro-
mote ubiquitination of Hsp90 client proteins (Xu et al., 2002), 
we asked whether there was also an increase in the levels of 
ubiquitinated  proteins  in  oz-apraA–treated  cells.  Like  GA, 
treatment with oz-apraA significantly induced accumulation 
of endogenous or transfected polyubiquitin-positive proteins 
(Fig. 3, A and B). Importantly, as shown in Fig. 3 B, oz-apraA 
significantly induced ubiquitination of EGFR. Because the 
lysosomal inhibitor ammonium chloride (NH4Cl) inhibited 
also showed high similarity to that of Hsp90 inhibitors (Fig. S1 C). 
Because immediate cellular responses are more likely to be the 
result of direct interaction with the primary targets, we hypoth-
esize that the mechanism of apratoxin A action might share 
similarity to that of GA and act by modulating Hsp90 complex 
formation with its client proteins.
Investigation of the apratoxin A mechanism of action has 
been hampered by the scarcity of natural material. Because 
our  previous  work  demonstrated  that  oz-apraA,  which  has 
similar potency with respect to tumor toxicity as apratoxin A, 
could be obtained through total synthesis (Ma et al., 2006), we 
next examined the impact of oz-apraA on activation of the 
Hsp90 pathway.
We first determined the effect of oz-apraA on the protein 
levels of the Hsp90 client proteins. Treatment with oz-apraA led 
to concentration- and time-dependent reductions in the protein 
levels of known Hsp90 clients, EGFR, ErbB2 (Fig. 1 B and 
Fig. S1 D), and RIP-1 (see Fig. 4 D). In A549 cells, wild-type 
EGFR is more sensitive to oz-apraA than to GA. Although, in 
MDA-MB-453 cells, the treatment with 10 nM oz-apraA or GA 
for 24 h led to a similar reduction in the levels of ErbB2 (Fig. 1 B, 
bottom). Oz-apraA treatment also led to a dose-dependent in-
crease in the levels of Hsp70 (Hsp/Hsc70), as detected by an 
antibody recognizing both Hsp70 and Hsc70, but to a lesser extent 
than that with GA treatment (Fig. 1 B). We further tested whether 
oz-apraA had any effect on the half-life of EGFR (Fig. 1 C). 
Although the levels of EGFR did not change appreciably over 
24 h in the presence of cycloheximide (CHX) alone, in the pres-
ence of oz-apraA and CHX, a reduction in the levels of EGFR 
was first detected at 8 h. By 24 h, <20% remained. In contrast, 
oz-apraA had no effect on the turnover of interleukin 6 signal 
transducer GP130 (Fig. 1 C) or the turnover of pEGFP-CL1 
(see Fig. 3 D), suggesting that oz-apraA does not directly inhibit 
proteasome activity. Furthermore, 500 nM oz-apraA or up to 
1 µM GA had no effect on the levels of FGFR1, a non-Hsp90 
client membrane receptor (Fig. S1 E; Citri et al., 2006). From 
these results, we conclude that oz-apraA specifically reduces 
the levels of at least a subset of Hsp90 client proteins.
The GA class of Hsp90 inhibitors binds to the N-terminal 
ATP-binding site of Hsp90 with higher affinity than that of natu-
ral nucleotides and thus abrogates the formation of Hsp90 
chaperone–client protein complexes by preventing exchange of 
ADP for ATP (Whitesell and Lindquist, 2005). To determine 
whether oz-apraA also disrupts the interaction of Hsp90 with its 
client proteins, we examined the interaction of Hsp90 with ErbB2 
by coimmunoprecipitation. We found that like GA, treatment of 
MDA-MB-453 cells with oz-apraA reduced the interaction of 
Hsp90 with its client protein, ErbB2 (Fig. 1 D). Furthermore, in 
the presence of 100 nM oz-apraA, the interaction of Hsp90 with 
ErbB2 in SKoV3 cell lysates was inhibited to the same extent as 
in cells treated with 1 µM GA (Fig. 1 E). From these data, we 
conclude that oz-apraA can inhibit the physical interactions of 
Hsp90 with at least a subset of its clients.
Oz-apraA–binding proteins
To identify oz-apraA target proteins, we generated a biotin deriv-
ative of oz-apraA (bio–oz-apraA) with a spacer at position 26 of JCB • VOLUME 185 • NUMBER 4 • 2009   632
in transfected HEK293 cells, whereas oz-apraA and GA had no 
effect (Fig. 3 D). Because oz-apraA also had no effect on the half-
life of short-lived protein GP130 (Fig. 1 C), we conclude that 
oz-apraA does not inhibit the proteasomal pathway.
Oz-apraA–induced degradation of EGFR is 
independent of proteasome  
or macroautophagy
Because the proteasomal pathway is critical for the degradation of 
most of the known Hsp90 client proteins when the Hsp90 com-
plex function is abrogated by Hsp90 inhibitors (Zhang and 
Burrows, 2004; Qing et al., 2006), we investigated whether the 
enhanced turnover of Hsp90 client proteins in oz-apraA–treated 
cells also involves the proteasome. In contrast to GA, MG132 
failed to inhibit the degradation of Hsp90 client proteins induced 
by oz-apraA in different cell lines, whereas NH4Cl could block 
oz-apraA–induced Hsp90 client protein degradation (Fig. 4 A). 
Consistent with a function of lysosomes in this context, a signifi-
cantly increased amount of EGFR was colocalized with LAMP-1–
RFP upon treatment of oz-apraA in A549 cells (Fig. 4 B). 
However, the presence of MG132 but not NH4Cl inhibited 
the degradation of ErbB2 induced by GA (Fig. S4 A), as reported 
previously (Peng et al., 2005). Collectively, these results sug-
gest that contrary to GA, the degradation of Hsp90 clients 
induced by oz-apraA is dependent on lysosomal, not protea-
somal, mechanisms.
oz-apraA–mediated EGFR degradation (see Fig. 4 A), we 
observed that combining treatment of oz-apraA and NH4Cl 
further enhanced oz-apraA–mediated EGFR ubiquitination. 
In comparison, although both GA and MG132 treatments in-
duced total cellular polyubiquitin accumulation, they were much 
less effective at inducing polyubiquitination of EGFR (Fig. 3 B).
Oz-apraA–induced ubiquitin accumulation was also sup-
ported by an immunofluorescence experiment using antiubiqui-
tin. As shown in Fig. 3 C, oz-apraA led to the appearance of 
ubiquitin-positive protein aggregation around the nuclear mem-
brane, which partially colocalized with Hsp70/Hsc70. The pro-
minent single juxtanuclear body (Fig. 3 C, 6-h treatment) resembled 
an aggresome, which forms in the proximity of the microtubule-
organizing center as a result of accumulating misfolded proteins 
(Xu et al., 2002). The colocalization of Hsp70 and -tubulin in 
protein aggregates induced by oz-apraA provided a further con-
firmation of aggresome (Fig. S3).
Because oz-apraA treatment for 2 h was sufficient to induce 
the accumulation of aggregated ubiquitin (Fig. 3 C), we asked 
whether oz-apraA directly inhibited proteasome activity, which 
might be responsible for the accumulation of ubiquitinated pro-
teins. We used a reporter consisting of a short degron, CL1, fused 
to the C terminus of EGFP (pEGFP-CL1; Bence et al., 2001). 
HEK293  cells  transiently  transfected  with  pEGFP-CL1  were 
treated with MG132, oz-apraA, or GA individually. As expected, 
the presence of MG132 increased the fluorescence of pEGFP-CL1 
Figure 2.  Oz-apraA–binding proteins. (A) Brief   
synthetic steps of bio–oz-apraA. CuI, cuprous   
iodide;  I-Pr2NEt,  diisopropyl-ethyl  amine; 
CH3CN, acetonitrile. (B) The pull-down prod-
ucts from bio–oz-apraA using HeLa cells were   
separated by SDS-PAGE and visualized by 
silver staining. The data from mass spectrom-
etry analysis are shown in the table. Lane 1, 
streptavidin-agarose  beads;  lane  2,  bio– 
oz-apraA  incubation  followed  by  pulling 
down by streptavidin-agarose beads; lane 3, 
the presence of excess oz-apraA. recover pep, 
recovery peptides of the enzyme digestion. 
(C) Confirmation of bio–oz-apraA endogenous 
binding  protein  (Hsp/Hsc70)  in  HeLa  and 
HEK293 cell lysates by Western blotting. Lane 
1, DMSO; lane 2, first incubation with DMSO 
followed by incubation with 2 µM bio–oz-apraA; 
lane 3, first incubation with 20 µM oz-apraA 
followed  by  incubation  with  2  µM  bio–oz-
apraA. (D) Bio–oz-apraA binds to both Hsp70 
and Hsc70 proteins. HEK293 cells were tran-
siently transfected with the indicated plasmids, 
and the pull-down assay was performed as de-
scribed in Materials and methods after West-
ern blotting using anti-HA antibody. Lanes 1 
and 4, DMSO; lanes 2 and 5, first incubation 
with DMSO followed by incubation with 2 µM 
bio–oz-apraA; lanes 3 and 6, first incubation 
with 20 µM oz-apraA followed by incubation 
with 2 µM bio–oz-apraA. IB, immunoblotting.633 HSP90 CLIENTS’ DEGRADATION THROUGH CMA • Shen et al.
that oz-apraA–induced degradation of EGFR is not through 
macroautophagy by using Atg5-deficient mouse embryonic 
fibroblast (MEF) cells. Atg5 is essential for autophagosome 
formation, and Atg5 deficiency blocks macroautophagy (Kuma 
et  al.,  2004).  Oz-apraA  induced  degradation  of  EGFR  as   
efficiently  in  Atg5
/  MEFs  in  an  NH4Cl
-sensitive  but 
MG132-insensitive  manner  as  that  in  the  Atg5
+/+  MEFs   
(Fig. 5 C, left).
Finally,  we  found  that  oz-apraA  did  not  increase  the 
amount of acidic lysosomes, whereas the positive control, nige-
ricin, could significantly increase the numbers of acidic lyso-
some (Fig. S4 B). Thus, oz-apraA does not act by stimulation of 
lysosomal activity per se. Collectively, these findings indicate 
that it is unlikely that oz-apraA–induced degradation of Hsp90 
client proteins is mediated through the proteasome pathway, 
macroautophagy, or by increasing number of lysosomes.
We also monitored the endocytosis of rhodamine-labeled 
EGF upon treatment with oz-apraA and GA (Fig. S4 C), and 
neither of them affected EGF internalization. Thus, we further 
excluded a possible effect of oz-apraA on endocytosis.
Because macroautophagy and microautophagy are also 
lysosomal-dependent  protein  degradation  mechanisms,  we 
first examined whether oz-apraA had any effects on macro-
autophagy. LC3 (microtubule-associated protein 1 light chain 3) 
is the mammalian orthologue of yeast Atg8 (Kabeya et al., 
2000). The conversion of cytosolic LC3-I to lipidated LC3-II, 
which  is  associated  with  autophagosome  membrane,  is  a 
well-established marker for macroautophagy (Kabeya et al., 
2000). Vesicle-localized GFP-LC3 is a sensitive assay to detect 
autophagosome formation (Kabeya et al., 2000). In contrast 
to rapamycin, the treatment with oz-apraA did not increase 
the number of LC3-positive autophagic vesicles in H4 cells 
(Fig. 5 A, 4 h and 9 h). More importantly, the treatment of 
oz-apraA alone did not increase the levels of LC3-II (Fig. 5 B). 
In fact, as predicted by the microarray analysis (Fig. S1 B, 6-h 
treatment), oz-apraA inhibited autophagy, as evident by the 
reduced basal levels of LC3-II in HeLa cells (Fig. 5 B, lane 3). 
Furthermore, pretreatment with oz-apraA abrogated rapamycin-
induced LC3-II increases (Fig. 5 B, lane 4), suggesting that 
oz-apraA  inhibits  macroautophagy.  We  further  confirmed 
Figure  3.  Oz-apraA  induces  the  accumula-
tion of ubiquitinated proteins and the forma-
tion  of  aggresomes.  (A)  100  nM  oz-apraA 
and1  µM  GA  induce  the  accumulation  of 
endogenous ubiquitinated proteins in HeLa cells. 
(B) Oz-apraA promotes the ubiquitination of 
EGFR. HEK293 cells were transfected with 2 µg 
pcDNA3-EGFR  and  2  µg  wild-type  pcDNA-
HA-ubiquitin (Ub) followed by treatment with 
the indicated compounds for 6 h. EGFR was 
immunoprecipitated  from  the  lysates,  and 
ubiquitinated EGFR were detected with anti-
HA antibody by Western blotting. IP, immuno-
precipitation.  (C)  Oz-apraA  promotes  the 
accumulation of ubiquitinated proteins. HeLa 
cells were treated with 100 nM oz-apraA for 
the indicated times followed by immunostaining 
with antiubiquitin (green), anti-Hsp/Hsc70 (red), 
and DAPI (blue) as indicated. Superimposed 
confocal images (merge) demonstrate the co-
localization of ubiquitin with Hsp/Hsc70. Arrow-
heads  indicate  the  colocalization  of  ubiquitin 
and Hsp/Hsc70. Bar, 10 µm. (D) Oz-apraA   
does not inhibit proteasome activity. pEGFP-
CL1–transfected HEK293 cells were treated with 
or without 100 nM oz-apraA, 5 µM MG132, or 
1 µM GA for 12 h. Bar, 50 µm.JCB • VOLUME 185 • NUMBER 4 • 2009   634
Because  Hsc70  has  been  recognized  as  an  important 
chaperone in mediating CMA (Bandyopadhyay and Cuervo, 
2008), the requirement of Hsc70 suggests the possibility that 
oz-apraA might promote the degradation of Hsp90 client pro-
teins through CMA. Because LAMP-2A recognition is a rate-
limiting step in CMA (Kiffin et al., 2004), we further determined 
whether inhibition of LAMP-2A receptor expression could abro-
gate the oz-apraA–induced degradation of Hsp90 client pro-
teins. Knockdown of LAMP-2A by vector-mediated RNAi 
significantly inhibited oz-apraA–induced EGFR and/or ErbB2 
degradation in different cell lines, whereas GA-induced ErbB2 
and/or  EGFR  degradation  was  not  affected  (Fig.  6  E  and   
Fig. S5 B). These findings suggest that oz-apraA modulates 
Hsp90 chaperone complexes and enhances the interaction of 
Hsp90 client proteins and Hsc70, which can then be recognized 
by LAMP-2A for degradation via CMA.
CMA substrate KFERQ motif is required 
for oz-apraA–induced EGFR degradation
Cytosolic Hsc70 recognizes a peptide sequence that includes 
the KFERQ-like motif in its substrate proteins (Chiang et al., 
1989). We noted that the EGFR sequence contains a pentapeptide 
Oz-apraA induces the degradation of 
Hsp90 client proteins through CMA
Because bio–oz-apraA was able to bind Hsp70/Hsc70, we next 
examined the interaction of Hsp70/Hsc70 with EGFR in cells 
treated with oz-apraA. Interestingly, although the total levels of 
Hsp70/Hsc70 in oz-apraA–treated cells were not increased as 
dramatically as in GA-treated cells, an increased association of 
Hsp70/Hsc70 with EGFR or ErbB2 was observed after oz-apraA 
treatment (Fig. 6, A and B).
Because  our  antibody  does  not  distinguish  Hsp70  or 
Hsc70, we asked whether oz-apraA can differentiate between 
Hsp70 and Hsc70 using transgenes. We transfected HEK293 
cells with pcDNA-HA-Hsc70 or pcDNA-HA-Hsp70 together 
with pcDNA3-EGFR. As shown in Fig. 6 C, oz-apraA induced 
interaction of EGFR with both Hsc70 and Hsp70, whereas 
GA could only induce interaction of EGFR with Hsp70, which 
is consistent with a previous study (Doong et al., 2003). How-
ever, knocking down the expression of Hsc70 but not Hsp70 
or Hsp90 partially abrogated oz-apraA–induced EGFR degra-
dation (Fig. 7 D and Fig. S5 A), suggesting that the interaction 
of oz-apraA with Hsc70 but not Hsp70 may play an important 
functional role in promoting the degradation of EGFR.
Figure 4.  Oz-apraA induces Hsp90 client protein deg-
radation through lysosomal pathway. (A) Lysosomal in-
hibitor abrogates oz-apraA–induced Hsp90 client protein 
degradation. A549 cells (left) and MDA-MB-453 cells 
(right) were pretreated with the indicated compounds for 
2 h followed by treatment of 50 nM oz-apraA for 24 h. 
Cell lysates were separated by SDS-PAGE. The Western 
blot was probed with anti-EGFR, anti-RIP1, and anti-ErbB2 
antibodies. Anti–-tubulin was used as a loading control. 
(B) Immunolocalization of EGFR and lysosomal marker 
LAMP-1 in A549 cells before and after treatment with 
oz-apraA in the presence of 20 mM NH4Cl. A549 cells 
were transiently transfected with LAMP-1–RFP expression 
plasmid, and after a 24-h transfection, cells were treated 
with or without 50 nM oz-apraA and 20 mM NH4Cl for 
6 h, fixed, permeabilized, and stained with anti-EGFR 
rabbit polyclonal antibody. Arrows indicate the colocal-
ization of EGFR and LAMP-1. Bar, 15 µm.635 HSP90 CLIENTS’ DEGRADATION THROUGH CMA • Shen et al.
translocation into the lysosomal lumen (Cuervo et al., 2004). 
Interestingly, we found that in oz-apraA–treated cells, although 
the levels of wild-type EGFR were resistant to the effect of 
MG132 and sensitive to NH4Cl, the levels of EGFR(AA) 
became sensitive to MG132 but resistant to NH4Cl (Fig. 7 C). 
From these results, we conclude that the pentapeptide sequence 
(756NKEIL760) of EGFR is required for the oz-apraA–induced 
EGFR  degradation  through  CMA.  The  requirement  for  the 
NKEIL polypeptide sequence also supports the involvement of 
CMA in oz-apraA–induced EGFR degradation rather than other 
lysosomal-mediated processes such as microautophagy.
Discussion
Hsp90 has emerged as an exciting molecular target for cancer 
therapy. Promoting the degradation of Hsp90 client proteins, 
many of which are important positive regulators of cell growth 
and proliferation, provides the key underlying mechanism for 
the success of anti-Hsp90 therapy. We demonstrate in this study 
that oz-apraA also specifically and potently induces the degra-
dation of at least a subset of Hsp90 client proteins. Although 
most of the known inhibitors of Hsp90 function by interrupting 
the intrinsic ATPase activity of Hsp90 and promoting the deg-
radation  of  the  client  proteins  via  the  ubiquitin-proteasome 
pathway, we show that oz-apraA induces the degradation of 
Hsp90 client proteins through CMA, a lysosomal degradation 
mechanism distinct from proteasome-dependent mechanisms. 
Our study provides the first example for the ability of CMA to 
mediate the degradation of membrane receptors and the cross 
talk of CMA and proteasomal degradation mechanisms.
The Hsp90 chaperone–client protein cycle involves suc-
cessive association and dissociation of several cochaperones to 
form various multimeric protein complexes and is dictated by 
the ATP-binding state of Hsp90. A client protein initially asso-
ciates with an Hsp70–Hsp40 complex and is then bound to 
Hsp90 via HOP (Hsp90/Hsp70-organizing protein). A confor-
mational change in Hsp90, induced by ATP hydrolysis, leads to 
the release of Hsp70–Hsp40 and HOP and association of other 
cochaperones to form a mature complex (Sharp and Workman, 
2006). Increased association of Hsp70 with Hsp90 client pro-
teins in cells treated with GA might reflect an inability to release 
the cochaperones from Hsp90 client proteins. By the same   
analogy, the increased association of not only Hsp70 but also 
Hsc70 with Hsp90 client proteins in cells treated with oz-apraA 
suggests that at least a subpopulation of Hsp90 client proteins 
might regularly interact with Hsc70.
Although Hsc70 and Hsp70 are highly homologous (86% 
identity in amino acid sequence), only Hsc70 but not Hsp70 has 
been implicated in mediating CMA as a molecular chaperone 
that  stimulates  cargo  protein  translocation  across  membrane 
(Bandyopadhyay and Cuervo, 2008). Hsc70 is constitutively 
expressed and has also been found to be a part of Hsp90 com-
plex and interact with HOP (Gebauer et al., 1997). Interestingly, 
Hsp90 megacomplexes, including Hsp90, Hsp40, HOP, Hsp70-
interacting protein, and BAG-1 (Bcl-2–associated athanogene 1 
protein), were found to be associated with the cytosolic side of 
the lysosomal membrane in cells under prolonged starvation 
sequence (756NKEIL760) that is consistent with a CMA recogni-
tion motif (Dice, 2007), and this pentapeptide sequence is highly 
conserved between EGFR and ErbB2 in human and mouse, 
located in the C helix of the kinase domain (Fig. 7 A). We asked 
whether this motif was required for oz-apraA–induced EGFR 
degradation through the lysosomal pathway. We generated a mu-
tant EGFR construct expressing a mutated EGFR with the se-
quence 756NKEIL760 replaced by 756AAEIL760, termed EGFR(AA). 
Although endogenous EGFR in HEK293 cells was barely de-
tectable, transiently transfected wild-type and EGFR(AA) ex-
pression constructs were expressed at comparable levels (Fig. 7 B). 
However, the mutant of EGFR does not affect EGF-induced 
downstream signaling transduction (Fig. 7 B, EGFR and STAT 
[signal transducer and activator of transcription] phosphory-
lation) and/or EGF-stimulated EGFR endocytotic degrada-
tion (Fig. S4 D).
Mutation of the KFERQ motif impairs the association of 
mutant proteins with lysosomal membrane and reduces their 
Figure 5.  Oz-apraA does not induce Hsp90 client protein degradation 
through macroautophagy. (A) Stable GFP-LC3–expressed H4 cells were 
treated with 100 nM oz-apraA for 4 or 9 h or with 218 nM rapamycin for 
4 h. Bar, 10 µm. (B) Oz-apraA does not increase the levels of LC3-II. HeLa 
cells were treated with 200 nM rapamycin or 100 nM oz-apraA for 3 h 
except that in lane 4, cells were pretreated with 100 nM oz-apraA for 1 h 
followed by 200 nM rapamycin for an additional 3 h. The endogenous 
LC3-II levels were detected with anti-LC3 antibody and quantified rela-
tive to -tubulin. (C) Atg5 wild-type (+/+) or knockout (/) MEFs were 
treated with 100 nM oz-apraA, 5 µM MG132, and/or 20 mM NH4Cl as   
indicated for 24 h. Protein levels were detected with anti-EGFR and anti–
-tubulin antibodies.JCB • VOLUME 185 • NUMBER 4 • 2009   636
The EGFR family of receptors (EGFR [ErbB1], ErbB2, 
ErbB3, and ErbB4) are important regulators of normal growth 
and differentiation. Antagonizing the functions of EGFR family 
of receptors has been an important therapeutic strategy for the 
treatment of cancers. Oz-apraA–induced EGFR degradation re-
quires the 756NKEIL760 peptide for degradation through CMA. 
Interestingly, in a genomic screen for somatic cancer mutations 
from a subset of 58 nonsmall cell lung cancer samples that in-
cluded 41 lung adenocarcinomas, Paez et al. (2004) identified 
10 tumor samples that carried small deletions in EGFR for co-
dons 746–750 (Del-1) and one tumor sample that carried a dele-
tion of 752–759 (Del-2; Table S3), which deleted most of the 
CMA recognition sequence identified by us. Although the po-
tential  significance  of  such  deletions  for  the  degradation  of 
EGFR through CMA remains to be examined in future studies, 
we  propose  that  degradation  of  EGFR  through  CMA  might 
serve as a tumor suppressor mechanism by down-regulating 
EGFR levels.
Both GA and oz-apraA can induce the down-regulation of 
EGFR protein levels but through distinct mechanisms. Such 
down-regulation of EGFR may occur during the folding and 
ER-Golgi transport process before localization on the plasma 
membrane. Misfolded membrane proteins are known to be retro 
transported from the ER to the cytosol through ER-associated 
condition (Agarraberes and Dice, 2001). Thus, the cells may 
target the Hsp90 client proteins for degradation through lyso-
somal pathway under nutrient-limiting conditions.
A previous study has reported that the increase in total 
proteolysis induced by GA is reduced by the treatment of NH4Cl 
but not by 3-methyladenine, which inhibits macroautophagy 
but not CMA, which has led Finn et al. (2005) to suggest that 
GA also stimulates CMA. However, because a relatively high 
concentration of GA (2 µM) was used by Finn et al. (2005), the 
apparent induction of CMA might be a result of toxicity rather 
than a direct result of inhibiting Hsp90. Because the degrada-
tion of a vast majority of Hsp90 client proteins induced by GA 
depends  on  the  proteasomal  pathway  (Zhang  and  Burrows, 
2004) and because we found that GA does not induce the asso-
ciation of Hsc70 and Hsp90 client proteins, we propose that GA 
does not directly promote CMA.
Another  recent  study  has  reported  that  the  GA-induced 
degradation of IKK, which is also an Hsp90 client protein, is 
mediated by the macroautophagic pathway (Qing et al., 2006). 
In this case, the degradation of IKK was found to require Atg5, 
a gene required for macroautophagy but not for CMA. However, 
because a high concentration of 10 µM GA was used in this study, 
it is also possible that the toxicity of GA activates macroautoph-
agy, which in turn promotes the degradation of IKK.
Figure  6.  Oz-apraA  induces  Hsp90  client 
membrane protein degradation through CMA. 
(A) Interaction of EGFR and Hsp/Hsc70 after 
treatment  with  oz-apraA.  (B)  Oz-apraA  and   
GA both increase the interaction of ErbB2 and 
Hsp/Hsc70. (C) Oz-apraA but not GA induces 
the  interaction  between  Hsc70  and  EGFR. 
HEK293  cells  were  transfected  with  2  µg 
pcDNA3-EGFR  together  with  2  µg  pcDNA-
HA-Hsc70 or pcDNA-HA-Hsp70 for 24 h fol-
lowed by treatment with 100 nM oz-apraA or 
1 µM GA for an additional 12 h. The cells 
were  lysed,  and  the  lysates  were  immuno-
precipitated with anti-EGFR antibody followed 
by  immunoblotting  with  anti-HA  antibody  to 
detect the interaction of EGFR with Hsc70 or   
Hsp70. (D) Hsc70 RNAi could partially inhibit 
oz-apraA–induced  EGFR  degradation.  HeLa 
cells were transfected with siRNA specifically 
against Hsc70, Hsp70, or Hsp90 for 48 h 
followed by treatment with or without 100 nM   
oz-apraA  for  an  additional  12  h.  EGFR 
levels  were  quantified  to  that  of  -tubulin.   
(E) LAMP-2A was required for oz-apraA–induced 
Hsp90 client protein degradation. A549 cells 
(top  panels)  or  MDA-MB-453  cells  (bottom 
panels) were transiently transfected with pSuper-
LAMP-2A for 48 h and treated with 100 nM 
oz-apraA or 500 nM GA for 24 h. IP, immuno-
precipitation; L2A, LAMP-2A.637 HSP90 CLIENTS’ DEGRADATION THROUGH CMA • Shen et al.
CMA is not yet clear, Hsc70, a cytosolic chaperone essential for 
translocation of substrates via CMA, has been proposed as a 
good candidate for acting as a cross-talking molecule. Because 
experimental  loading  of  CMA-incompetent  lysosomes  with 
Hsc70 is sufficient to activate CMA capability, increased expres-
sion or localization of Hsc70 within a particular subcellular area 
may activate CMA. We propose that an increased interaction of 
EGFR with Hsc70 induced by oz-apraA is sufficient to promote 
the degradation of EGFR through the CMA.
Materials and methods
Cells and reagents
A549, MDA-MB-453, HEK293, SKoV3, and H4 cells were cultured in 
DME containing 10% FCS (Hyclone). The sources of chemicals, peptides, 
and antibodies were as follows: GA and MG132 (EMD), rapamycin and 
nigericin (BIOMOL International L.P.), ammonium chloride (Shanghai Re-
agents, Inc.), recombinant human EGF (Invitrogen), DAPI (Sigma-Aldrich), 
lysotracker (Invitrogen), secondary HRP-conjugated antibodies (Jackson 
ImmunoResearch Laboratories), secondary FITC- and TRITC-conjugated anti-
bodies (Shanghai Kangcheng), mouse anti–-tubulin (Santa Cruz Biotech-
nology,  Inc.),  rabbit  anti-EGFR  (Cell  Signaling  Technology),  mouse 
anti-Hsp70/Hsc70 (Santa Cruz Biotechnology, Inc.), rabbit anti-GP130 
(Santa Cruz Biotechnology, Inc.), mouse antiubiquitin (Cell Signaling Tech-
nology), rabbit anti-LC3 (Novus Biologicals), mouse anti-HA (Tiangen), rabbit 
anti-ErbB2 (Cell Signaling Technology), mouse anti-Hsp90 (BD), mouse anti-
RIP1 (BD), rabbit antiphospho-EGFR (Y1068; Invitrogen), rabbit antiphospho-
STAT1 (Y701; Cell Signaling Technology), mouse antiphospho-STAT3 
degradation and degraded through proteasomal pathway (Strous 
and Gent, 2002). The ability of oz-apraA to induce the appear-
ance of aggresomes without impairing the function of protea-
somes is consistent with a significant increase in the retro transport 
of misfolded proteins from the ER to the cytosol through ER-
associated degradation. Alternatively, oz-apraA–induced down-
regulation of EGFR may occur after ligand binding and receptor 
activation during receptor recycling and degradation process, 
which is mediated through clathrin-coated endocytic vesicles 
and subsequent fusion with early endosomes (Roepstorff et al., 
2008). The ability of oz-apraA to dramatically stimulate the 
polyubiquitination of EGFR in an NH4Cl
-sensitive manner is 
also consistent with the possibility that oz-apraA may be able to 
promote  the  polyubiquitination  and  degradation  of  ligand-
bound EGFR. The exact form of EGFR that is degraded after 
oz-apraA treatment needs to be further characterized.
The existence of cross talks between different forms of 
autophagy pathways has been proposed by Massey et al. (2006a). 
It was reported that the cells with impaired CMA function were 
able to maintain homeostatic protein degradation through up-
regulation of macroautophagy (Massey et al., 2006b). Thus, inhi-
bition of macroautophagy by oz-apraA at later time points may 
also contribute to further induction of CMA. Although the molecu-
lar mechanism that mediates the cross talk of macroautophagy and 
Figure 7.  KFERQ motif is required for EGFR deg-
radation through CMA upon oz-apraA treatment. 
(A) Sequence alignment of the EGFR family mem-
bers from human and mouse. The C helix contains 
a 756NKEIL760 pentapeptide sequence (yellow box), 
which is known as a KFERQ motif recognized by 
CMA.  Pink  regions  indicate  the  homogeneity  of 
the  amino  acid  between  EGFR  family  proteins, 
and purple and red regions indicate the discrep-
ancy between ErbB3 and other members. N, Asn; 
,  basic  amino  acid;  +,  acidic  amino  acid;   
, hydrophobic amino acid; *, Hsp90-binding sites. 
(B) HEK293 cells were transfected with wild-type 
(WT) EGFR or EGFR(AA) for 24 h and stimulated 
with 100 ng/ml EGF for 5 min. The levels of se-
lected  EGFR  downstream  protein  phosphoryla-
tion were detected using specific anti–p-STAT1, 
anti–p-STAT3, and anti–p-EGFR(Y1068) antibodies. 
Anti-GAPDH was used as a loading control. Black 
lines  indicate  that  intervening  lanes  have  been 
spliced out. (C) The treatment of oz-apraA induces 
the  degradation  of  EGFR(AA)  through  MG132-
sensitive proteasome pathway. HEK293 cells were 
transfected with wild-type EGFR or EGFR(AA) for 
24 h and treated with 100 nM oz-apraA, 5 µM 
MG132, or 20 mM NH4Cl for an additional 24 h. 
The cells were lysed, and the degradation of EGFR 
was analyzed using anti-EGFR by Western blotting. 
Anti–-tubulin was used as a loading control.JCB • VOLUME 185 • NUMBER 4 • 2009   638
with agitation overnight, and streptavidin-agarose was added to pull-down 
bio–oz-apraA protein complex by incubating at 4°C for 3 h. After brief 
centrifugation, pellets were boiled in 2× SDS loading buffer for 5 min, 
samples were separated by SDS-PAGE, and pulled-down proteins were 
identified by silver staining.
Chemical data
The following data describe the results of nuclear magnetic resonance of bio–
oz-apraA: 
1H nuclear magnetic resonance (500 MHz, CDCl3)  7.13 (m, 2H), 
6.78 (m, 2H), 6.49 (d, J = 7.8 Hz, 1H), 6.19 (d, J = 9.5 Hz, 1H), 5.82 
(brs, 1H), 5.30 (m, 1H), 5.21 (d, J = 11.7 Hz, 1H), 5.07 (m, 1H), 4.96 
(d, J = 12.6 Hz, 1H), 4.88 (m, 1H), 4.77 (m, 1H), 4.65 (d, J = 10.9 Hz, 1H), 
4.52 (m, 1H), 4.36–4.26 (m, 4H), 4.25–4.10 (m, 3H), 3.91 (t, J = 6.6 Hz, 
2H), 3.66 (m, 2H), 3.29 (m, 1H), 3.25–3.14 (m, 4H), 3.12 (t, J = 11.7 Hz, 
1H), 3.04 (m, 1H), 2.93 (dd, J = 4.9, 12.8 Hz, 1H), 2.84–2.81 (m, 3H), 
2.81–2.67 (m, 6H), 2.63 (s, 1H), 2.42 (m, 1H), 2.33 (m, 1H), 2.28–2.11 
(m, 4H), 2.11–1.99 (m, 2H), 1.96–1.84 (m, 6H), 1.74 (m, 6H), 1.66 
(m, 6H), 1.46 (m, 6H), 1.39–1.29 (m, 8H), 1.29–1.24 (m, 4H), 1.22 
(m, 4H), 1.11–1.03 (m, 5H), 1.02–0.91 (m, 8H), 0.91–0.79 (m, 10H); 
ESIMS m/z 1329 [M+H]
+. High-resolution mass spectrometry calculated for 
C71H114N11O11S
+ [M+H]
+, which requires 1328.8415, found 1328.8457.
Online supplemental material
Fig. S1 shows that apratoxin A and its analogue oz-apraA induce degra-
dation of Hsp90 client proteins. Fig. S2 shows that oz-apraA disrupts 
the interaction of Hsp90 and Hsp70/Hsc70 at a later time point (8 h). 
Fig. S3 shows that oz-apraA induces aggresome formation in HeLa cells. 
Fig. S4 shows that oz-apraA–mediated Hsp90 client degradation is not 
through endocytosis and/or through inducing lysosomes. Fig. S5 shows 
the efficiency of siRNA knockdown on different proteins. Table S1 shows 
class neighbor gene signatures of apratoxin A for 3-h treatment. Table S2 
shows class neighbor gene signatures of apratoxin A for 6-h treatment. 
Table S3 shows the Del-2 somatic mutation in human nonsmall cell lung 
cancers.  Online  supplemental  material  is  available  at  http://www.jcb 
.org/cgi/content/full/jcb.200810183/DC1.
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